Shots:

• Medtronic enrolls the first patient in the ALLEVIATE-HF clinical trial assessing the ability of its Reveal LINQ ICM in identifying patients at high risk of worsening HF. The study will enroll ~300 patients at up to 30 sites across the US for a minimum of 7mos.and up to 3yrs.
•  The focus of the study is to determine if early information provided by the LINQ devices enables clinicians to act before patients' conditions worsen. The ICM allows physicians to monitor a patient’s heart continuously and wirelessly for arrhythmia disorder
• The Reveal LINQ ICM is ~ one-third the size of a AAA battery (~1 cc) and is placed just beneath the skin through a small incision of less than 1 cm in the upper left side of the chest- using a minimally invasive procedure. ALLEVIATE-HF trial is the first to study the use of an ICM to manage heart failure in a remote setting

­ Ref: Medtronic | Image: WebMD